Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$106.34 USD

106.34
5,027,239

-0.39 (-0.37%)

Updated Sep 22, 2023 04:00 PM ET

After-Market: $106.33 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.32%
2Buy18.06%
3Hold9.37%
4Sell5.20%
5Strong Sell2.60%
S&P50010.90%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (197 out of 245)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

by Zacks Equity Research

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications

by Kinjel Shah

The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

Merck (MRK) Stock Moves -0.54%: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $106.73, marking a -0.54% move from the previous day.

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.

Merck (MRK) Stock Moves -0.05%: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $107.31, marking a -0.05% move from the previous day.

FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma

by Zacks Equity Research

The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

by Zacks Equity Research

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.

Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug

by Zacks Equity Research

Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

Merck (MRK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $108.24, moving +0.4% from the previous trading session.

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

by Zacks Equity Research

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) closed the most recent trading day at $107.81, moving -1.11% from the previous trading session.

Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies

by Zacks Equity Research

The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.

Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up

by Zacks Equity Research

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.

Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study

by Zacks Equity Research

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.

Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NULV

Kinjel Shah headshot

Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe

by Kinjel Shah

The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.

Kinjel Shah headshot

Pharma Stock Roundup: J&J to End Hypertension Study & Other Regulatory Updates

by Kinjel Shah

J&J (JNJ) to end a late-stage study on macitentan for CTEPH. Merck's (MRK) Ebola vaccine gets approval in Europe for use in kids.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $107.94, marking a +1.36% move from the previous day.

Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?

by Zacks Equity Research

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $109.84, marking a +0.79% move from the previous day.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates

by Kinjel Shah

J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.

Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal

by Zacks Equity Research

Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.